Document Detail

Venous gas embolism during foam sclerotherapy of saphenous veins despite recommended treatment modifications.
MedLine Citation:
PMID:  21087951     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To investigate the effectiveness of methods proposed to prevent venous gas embolism during foam sclerotherapy.
METHODS: Transthoracic echocardiography was performed concurrent with ultrasound-guided sclerotherapy (UGS) of great or small saphenous veins. A volume of 2.5 mL of 3% sodium tetradecyl sulphate foam was prepared following the Tessari method and injected slowly 5-10 cm away from saphenous junctions. The procedure was repeated with modifications including using a 5 µm filter to generate microfoam, carbon dioxide as the foaming gas, leg elevation before or after the injection and immobility post-treatment.
RESULTS: Bubbles entered the right heart in less than 60 seconds and continued for up to 50 minutes despite all treatment modifications. None of the patients had a patent foramen ovale and none developed any neurological or cardiac symptoms.
CONCLUSION: Bubble emboli entered the heart during foam UGS of saphenous veins despite all treatment modifications and low volumes of foam used.
K Parsi
Publication Detail:
Type:  Journal Article     Date:  2010-11-18
Journal Detail:
Title:  Phlebology / Venous Forum of the Royal Society of Medicine     Volume:  26     ISSN:  1758-1125     ISO Abbreviation:  Phlebology     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-06-21     Completed Date:  2011-10-13     Revised Date:  2011-11-10    
Medline Journal Info:
Nlm Unique ID:  9012921     Medline TA:  Phlebology     Country:  England    
Other Details:
Languages:  eng     Pagination:  140-7     Citation Subset:  IM    
Sydney Skin and Vein Clinic, Sydney, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Embolism, Air / etiology*,  ultrasonography
Saphenous Vein*
Sclerosing Solutions / adverse effects*,  therapeutic use*
Sodium Tetradecyl Sulfate / adverse effects*,  therapeutic use*
Reg. No./Substance:
0/Sclerosing Solutions; 1191-50-0/Sodium Tetradecyl Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ranking prognosis markers in cancer genomic studies.
Next Document:  Cycloplegic and noncycloplegic refractions of Chinese neonatal infants.